↓ Skip to main content

BAP31, a promising target for the immunotherapy of malignant melanomas

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, April 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
BAP31, a promising target for the immunotherapy of malignant melanomas
Published in
Journal of Experimental & Clinical Cancer Research, April 2015
DOI 10.1186/s13046-015-0153-6
Pubmed ID
Authors

Shaojuan Yu, Fuli Wang, Li Fan, Yuying Wei, Haitao Li, Yuanjie Sun, Angang Yang, Boquan Jin, Chaojun Song, Kun Yang

Abstract

Malignant melanoma's (MM) incidence is rising faster than that of any other cancer in the US and the overall survival at 5 years is less than 10%. B cell associated protein 31 (BAP31) is overexpressed in most MMs and might be a promising target for immunotherapy of this disease. Firstly, we investigated the expression profiles of human BAP31 (hBAP31) and mouse BAP31 (mBAP31) in human and mouse normal tissues, respectively. The expression level of hBAP31 in human MMs and mBAP31 in B16 melanoma cells was also analyzed. Then we constructed novel mBAP31 DNA vaccines and tested there ability to stimulate mBAP31-specific immune responses and antitumor immunity in B16 melanoma-bearing mice. For the first time, we found that protein expression of hBAP31 were dramatically upregulated in human MMs when compared with human normal tissues. Predominant protein expression of mBAP31 was found in mouse B16 melanoma cells but not in mouse important organs. When mice were immunized with mBAP31 DNA vaccines, strong cellular response to mBAP31 was observed in the vaccinated mice. CTLs isolated from immunized mice could effectively kill mBAP31-positive target mouse B16 melanoma tumor cells in vitro and vaccination with mBAP31 DNA vaccines had potent anti-tumor activity in therapeutic model using B16 melanoma cells. These are the first data supporting a vaccine targeting BAP31 that is capable of inducing effective immunity against BAP31-expressing MMs and will be applicable to human MMs and hBAP31 DNA vaccine warrants investigation in human clinical trials.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 24%
Researcher 3 18%
Student > Bachelor 3 18%
Student > Doctoral Student 2 12%
Student > Master 2 12%
Other 2 12%
Unknown 1 6%
Readers by discipline Count As %
Agricultural and Biological Sciences 8 47%
Computer Science 2 12%
Immunology and Microbiology 2 12%
Biochemistry, Genetics and Molecular Biology 2 12%
Chemical Engineering 1 6%
Other 2 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 April 2015.
All research outputs
#4,207,587
of 5,033,253 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#213
of 309 outputs
Outputs of similar age
#140,671
of 169,828 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#15
of 24 outputs
Altmetric has tracked 5,033,253 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 309 research outputs from this source. They receive a mean Attention Score of 1.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,828 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.